David Cornblath

Medicine & Life Sciences

1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
2. Peripheral Nervous System Diseases 56%
3. Intravenous Immunoglobulins 50%
4. Peripheral Nerves 43%
5. Polyneuropathies 41%
6. Guillain-Barre Syndrome 35%
7. Hizentra 32%
8. Neural Conduction 27%
9. Diabetic Neuropathies 23%
10. Therapeutics 22%
11. Amyotrophic Lateral Sclerosis 22%
12. Guidelines 22%
13. Nerve Fibers 21%
14. Neurology 20%
15. Advisory Committees 20%
16. Antibodies 19%
17. Biopsy 18%
18. Immunoglobulins 18%
19. Demyelinating Diseases 16%
20. Drug Therapy 15%
21. Campylobacter jejuni 14%
22. Placebos 14%
23. Joints 14%
24. Plasmapheresis 14%
25. HIV 13%
26. G(M1) Ganglioside 13%
27. Campylobacter Infections 12%
28. Paralysis 12%
29. Mutation 12%
30. Motor Neurons 12%
31. Charcot-Marie-Tooth Disease 12%
32. Sural Nerve 11%
33. Muscles 11%
34. Immunoglobulin M 11%
35. Immunoglobulin G 11%
36. Plasma Exchange 11%
37. Gangliosides 10%
38. Tramadol 10%
39. Adrenal Cortex Hormones 10%
40. Cerebrospinal Fluid 10%
41. Randomized Controlled Trials 9%
42. Serum 9%
43. Electrophysiology 9%
44. Nervous System Diseases 9%
45. Action Potentials 9%
46. Skin 9%
47. Safety 9%
48. Electromyography 9%
49. Health Care Outcome Assessment 9%
50. Myasthenia Gravis 8%